<DOC>
	<DOCNO>NCT01238029</DOCNO>
	<brief_summary>The purpose study investigate safety efficiency triple combination capecitabine , lapatinib vinorelbine patient metastatic breast cancer .</brief_summary>
	<brief_title>Dose Finding Study Combination Capecitabine , Lapatinib Vinorelbine Metastatic Breast Cancer</brief_title>
	<detailed_description>The combination lapatinib capecitabine ist standard therapy f√ºr Her2 positive metastatic breast cancer . This study combine therapy additional antimitotic mode function vinorelbine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Key Written inform consent Able comply protocol ECOG performance status 01 Adequate contraception Confirmed Her2/neupositive , adenocarcinoma breast At least one measurable lesion accord RECIST 1.1 criterion First second chemotherapy diagnosis metastasis Lapatinib treatment indicate ( adjuvant trastuzumab treatment &lt; 12 month ago progressive disease trastuzumab treatment ) No sign symptom CHF ( chronic heart failure ) , LVEF ( leave ventricular ejection fraction ) study start least 55 % Adequate hepatic renal function value Adequate hematologic function value Pregnant lactate woman Concurrent participation another clinical trial . Prior participation allow last study medication administer 4 week prior randomization Asymptomatic regard tumor illness Previous treatment lapatinib , capecitabine vinorelbine Necessity plan treatment chemotherapeutics oder antihormone therapy Major surgical procedure , open biopsy significant traumatic injury within 28 day prior randomization , anticipation need major surgery course study Evidence cardiovascular disease , e.g . myocardial infection , unstable angina pectoris arrhythmia History vascular cardiovascular disease within past 6 month All illness result malabsorption oral medication inability take oral medication Concurrent treatment antiviral drug base sorivudine aminoglycosides Concurrent treatment drug interfere study medication , especially , induce CYP3A Concurrent treatment allopurinol Other malignancy ( except basal cell carcinoma skin cervical carcinoma situ ) ; patient include study recurrent disease observe least 5 year Concurrent illness circumstance could interfere trial participation , efficacy safety patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Dose finding study</keyword>
	<keyword>Combination</keyword>
</DOC>